B Siegerink1, F R Rosendaal, A Algra. 1. Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, the Netherlands.
Abstract
BACKGROUND: Confounding by common causes and reverse causation have been proposed as explanations for the association between high fibrinogen levels and cardiovascular disease. Genetic variants can alter fibrinogen characteristics and are not subject to these problems. OBJECTIVES: To determine the fibrinogen plasma levels for genotypic variants in fibrinogen-A alpha (FGA Thr312Ala) and fibrinogen-B beta (FGB - 455G/A), and whether these variants are associated with arterial thrombosis. METHODS: Fibrinogen genotypes were determined in a population-based case-control study including women aged 18-50 years; 218 cases with myocardial infarction, 192 cases with ischemic stroke, and 769 healthy controls. Fibrinogen levels were determined in the control population. RESULTS: The FGB - 455G/A variant increased plasma fibrinogen levels, whereas the FGA Thr312Ala variant lowered plasma fibrinogen levels, albeit to a modest extent. The risk of ischemic stroke was altered when the homozygote minor allele was compared with the homozygote major allele. The FGA Thr312Ala single-nucleotide polymorphism (SNP) was associated with a decrease in risk [odds ratio (OR) 0.43; 95% confidence interval (CI) 0.21-0.87], whereas the FGB - 455G/A SNP might have increased the risk (OR 1.76; 95% CI 0.7-4.03). The risk of myocardial infarction was not altered for either SNP (FGA Thr312Ala, OR 0.98, 95% CI 0.40-2.40; FGB - 455G/A, OR 0.98, 95% CI 0.40-2.40). CONCLUSIONS: With the genetic variations as markers of plasma fibrinogen levels alterations, thereby ruling out confounding and reverse causation, our results suggest that plasma fibrinogen levels could play a more pronounced role as risk factors for ischemic stroke than for myocardial infarction.
BACKGROUND: Confounding by common causes and reverse causation have been proposed as explanations for the association between high fibrinogen levels and cardiovascular disease. Genetic variants can alter fibrinogen characteristics and are not subject to these problems. OBJECTIVES: To determine the fibrinogen plasma levels for genotypic variants in fibrinogen-A alpha (FGA Thr312Ala) and fibrinogen-B beta (FGB- 455G/A), and whether these variants are associated with arterial thrombosis. METHODS:Fibrinogen genotypes were determined in a population-based case-control study including women aged 18-50 years; 218 cases with myocardial infarction, 192 cases with ischemic stroke, and 769 healthy controls. Fibrinogen levels were determined in the control population. RESULTS: The FGB- 455G/A variant increased plasma fibrinogen levels, whereas the FGA Thr312Ala variant lowered plasma fibrinogen levels, albeit to a modest extent. The risk of ischemic stroke was altered when the homozygote minor allele was compared with the homozygote major allele. The FGA Thr312Ala single-nucleotide polymorphism (SNP) was associated with a decrease in risk [odds ratio (OR) 0.43; 95% confidence interval (CI) 0.21-0.87], whereas the FGB- 455G/A SNP might have increased the risk (OR 1.76; 95% CI 0.7-4.03). The risk of myocardial infarction was not altered for either SNP (FGA Thr312Ala, OR 0.98, 95% CI 0.40-2.40; FGB- 455G/A, OR 0.98, 95% CI 0.40-2.40). CONCLUSIONS: With the genetic variations as markers of plasma fibrinogen levels alterations, thereby ruling out confounding and reverse causation, our results suggest that plasma fibrinogen levels could play a more pronounced role as risk factors for ischemic stroke than for myocardial infarction.
Authors: Christina L Wassel; Leslie A Lange; Brendan J Keating; Kira C Taylor; Andrew D Johnson; Cameron Palmer; Lindsey A Ho; Nicholas L Smith; Ethan M Lange; Yun Li; Qiong Yang; Joseph A Delaney; Weihong Tang; Geoffrey Tofler; Susan Redline; Herman A Taylor; James G Wilson; Russell P Tracy; David R Jacobs; Aaron R Folsom; David Green; Christopher J O'Donnell; Alexander P Reiner Journal: Blood Date: 2010-10-26 Impact factor: 22.113
Authors: Jonatan R Ruiz; Carmen Fiuza-Luces; Amaya Buxens; Amalia Cano-Nieto; Félix Gómez-Gallego; Catalina Santiago; Gabriel Rodríguez-Romo; Nuria Garatachea; José I Lao; María Morán; Alejandro Lucia Journal: Age (Dordr) Date: 2011-09-06
Authors: Elissa H Wilker; Stacey E Alexeeff; Audrey Poon; Augusto A Litonjua; David Sparrow; Pantel S Vokonas; Murray A Mittleman; Joel Schwartz Journal: Atherosclerosis Date: 2009-03-19 Impact factor: 5.162
Authors: Jillian Maners; Dipender Gill; Nathan Pankratz; Michael A Laffan; Alisa S Wolberg; Moniek P M de Maat; Symen Ligthart; Weihong Tang; Cavin K Ward-Caviness; Myriam Fornage; Stephanie Debette; Martin Dichgans; Barbara McKnight; Eric Boerwinkle; Nicholas L Smith; Alanna C Morrison; Abbas Dehghan; Paul S de Vries Journal: Blood Date: 2020-12-24 Impact factor: 22.113